Delving into the Latest Updates on Pittsburgh Compound B with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

(N-methyl-(11C))2-(4'-methylaminophenyl)-6-hydroxybenzothiazole, 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole, FSA-PIB AD

+ [4]

Target

APP

Mechanism

APP inhibitors(Beta amyloid A4 protein inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases

Active Indication

Multiple Sclerosis

Inactive Indication

Alcohol Use DisorderAlzheimer Disease

Originator Organization

University of Utah

Active Organization

Mayo Clinic

Inactive Organization

University of Pittsburgh

Avid Radiopharmaceuticals, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC14H12N2OS

InChIKeyZQAQXZBSGZUUNL-BJUDXGSMSA-N

CAS Registry566170-04-5

This clinical study will use the small molecule translocator protein (TSPO) ligand, 18F-labeled DPA- 714, to visualize and quantify neuroinflammation in treatment naivete women with stage 1-4 newly diagnosed ovarian cancer (without brain metastases) prior to starting neoadjuvant chemotherapy treatment (baseline) and within a month of completing first 6 cycles of cytotoxic chemotherapy treatment (follow-up). In addition, we will use the well-characterized small molecule PET(Positron Emission Tomography) tracer, 11C-labeled Pittsburgh compound B (PiB) to visualize and quantify the regional brain distribution of pathological amyloid deposition at baseline only. The brain amyloid PET and MRI data acquired through this study will be correlated with cognitive test data, clinical data, genetic testing, and biospecimens collected in this study.

Start Date01 Jun 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT06439992 / RecruitingNot ApplicableIIT

Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)

The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.

Start Date07 Nov 2023

Sponsor / Collaborator

Washington University School of Medicine

JPRN-UMIN000054523 / RecruitingIIT

Investigation of the molecular pathogenesis of cardiac amyloidosis using 18F-flutemetamol and 11C-PiB PET/CT and 99mTc-HMDP scintigraphy. - FMM, PiB, and HMDP accumulation in cardiac amyloidosis

Start Date11 Sep 2023

Sponsor / Collaborator

Kagawa University

100 Clinical Results associated with Pittsburgh Compound B

Login to view more data

100 Translational Medicine associated with Pittsburgh Compound B

Login to view more data

100 Patents (Medical) associated with Pittsburgh Compound B

Login to view more data

184

Literatures (Medical) associated with Pittsburgh Compound B

01 Sep 2024·Current Radiopharmaceuticals

Automated Synthesis of [¹¹C]PiB via [¹¹CH₃OTf]-as Methylating Agent for PET Imaging of β-Amyloid

Article

Author: Dixit, Manish ; Singh, Akhilesh K. ; Gambhir, Sanjay

Aim::Efficient synthesis of precursor from commercially available starting materials and automated radiosynthesis of [11C]PiB using commercially available dedicated [11C]- Chemistry module from the synthesized precursor.Background::[11C]PiB is a promising radiotracer for PET imaging of β-Amyloid, advancing Alzheimer's disease research. The availability of precursors and protocols for efficient radiolabelling foster the applications of any radiotracer. Efficient synthesis of PiB precursor was performed using anisidine and 4-nitrobenzoyl chloride as starting materials in 5 steps, having addition, substitutions, and cyclization chemical methodologies. This precursor was used for fully automated radiosynthesis of [11C]PiB in a commercially available synthesizer, MPS-100 (SHI, Japan). The synthesized [11C]PiB was purified via solid-phase methodology, and its quality control was performed by the quality and safety criteria required for clinical use.Methods::The synthesis of desired precursors and standard authentic compounds started with commercially available materials with 70-80% yields. The standard analytical methods were characterized all synthesized compounds. The fully automated [11C]-chemistry synthesizer (MPS-100) used for radiosynthesis of [11C]PiB with [11C]CH3OTf acts as a methylating agent. For radiolabelling, varied amounts of precursor and time of reaction were explored. The resulting crude product underwent purification through solid-phase cartridges. The synthesized radiotracer was analyzed using analytical tools such as radio TLC, HPLC, pH endo-toxicity, and half-life.Results::The precursor for radiosynthesis of [11C]PiB was achieved in excellent yield using simple and feasible chemistry. A protocol for radiolabelling of precursor to synthesized [11C]PiB was developed using an automated synthesizer. The crude radiotracer was purified by solid-phase cartridge, with a decay-corrected radiochemical yield of 40±5% and radiochemical purity of more than 97% in approx 20 minutes (EOB). The specific activity was calculated and found in a 110-121 mCi/μmol range.Conclusion::A reliable methodology was developed for preparing precursor followed by fully automated radiolabeling using [11C]MeOTf as a methylating agent to synthesize [11C]PiB. The final HPLC-free purification yielded more than 97% radiochemical purity tracer within one radionuclide half-life. The method was reproducible and efficient for any clinical center.

09 Aug 2024·Organic Letters

Utilization of a Branched Late-Stage Clickable Biotinylated Chassis on the Example of a Pittsburgh B Analogue

Article

Author: Özdüzenciler, Pelin ; Pietruszka, Jörg ; Weber, T Moritz ; Tamgüney, Gültekin

Biotinylation is probably the most frequent and practically useful modification of molecules to facilitate selective and highly affine binding to (strept)avidin for immobilization, enrichment, and purification for further (bio)chemical or (bio)physical investigations. We present a protecting-group-free synthesis of a branched biotin bis-azide that enables dual-payload late-stage functionalization with arbitrary alkynes via click chemistry. Utility of the chassis is briefly showcased on the example of a valuable Pittsburgh B analogue, which binds pathological protein aggregates, commonly found in neurodegenerative diseases.

06 Aug 2024·ACS Omega

Light Activated Release of Nitrile Ligands from trans-Ru(L)(PPh₃)₂(nitrile) Complexes

Article

Author: Hsu, Yu-Ting ; Davidson, Ross J. ; Beeby, Andrew ; Yufit, Dmitry S.

A series of trans-RuL(PPh₃)₂(nitrile) and {RuL(PPh₃)₂}.₂-μ-(nitrile)-based complexes [where L = 2,2'-(3,4-diphenyl-pyrrole-2,5-diyl)dipyridine (dpp), di(pyridin-2-yl)isoindoline-1,3-diimine (bpi), or 4-(4-methoxyphenyl)-6-phenyl-2,2'-bipyridine (Pbpy); and nitrile = 1,4-dibenzontirile, 4-ethynylbenzonitrile, or dicyanamide] were synthesized and characterized, and their electrochemical and photochemical behaviors were investigated. Those complexes that contained a significant nitrile contribution to their ³MLLCT show a release of their nitrile ligand (when L = dpp or Pbpy and the nitrile ligand = 4-dibenzontirile, or 4-ethynylbenzonitrile) with dissociation constants up to 8.09 × 10^-4 s^-1.

100 Deals associated with Pittsburgh Compound B

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Pittsburgh Compound B	-	DB15161

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	Phase 2	US	Mayo Clinic	10 Jul 2023
Alcohol Use Disorder	Discovery	US	University of Pittsburgh	01 Dec 2018
Alzheimer Disease	Discovery	US	Avid Radiopharmaceuticals, Inc.	01 Mar 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03958630 (CTgov)	Phase 1	Neurodegenerative Diseases \| Neuroinflammation \| Dementia	13	Positron Emission Tomography (PET) Scan+11C-ER176+11C-PIB (Healthy Volunteers)	hmjztbkwzm(frugwaokve) = qptijmnfgh hmgkromydk (fzdtclhjbm, egchewpktb - deubptostf) View more	-	01 May 2024
				Positron Emission Tomography (PET) Scan+11C-ER176+11C-PIB (Subjects With Frontotemporal Dementia (FTD))	hmjztbkwzm(frugwaokve) = dlfzryqyrx hmgkromydk (fzdtclhjbm, rbbtgqjdbe - rzgvjvfjhg) View more
AAIC2023	Not Applicable	-	60	11C-PIB-PET (Insulin resistance group (IR+))	hibpzlhpjs(eybbnrwjmf) = vouixrxtwb cjocekgtlc (vlrtsigeco ) View more	-	16 Jun 2023
				11C-PIB-PET (Control group (IR-))	hibpzlhpjs(eybbnrwjmf) = wihrssvzkd cjocekgtlc (vlrtsigeco )
AAIC2020	Not Applicable	-	23	[11C]-PIB (Amyloid-negative individuals)	qemlruhjma(qzybimuzhg) = ranhwpkvuk diklczylux (nnmjjvzfab )	-	07 Dec 2020
SNMMI2019	Not Applicable	-	-	[¹¹C]PiB	wnijqksurk(dhuzxctlrm) = jlkuamwzer epmffcfvne (ksgpnxmyfm )	-	21 May 2019
NCT01607476 (CTgov)	Phase 2	Alzheimer Disease	89	F18 Flutametamol+C11 PiB (Alzheimer's Disease)	tofhetlrzo(nfscdvkiyw) = xfbztqfsof mkcvjdoleb (sbthhipfck, jisgcmyxdu - mtqskjhthf) View more	-	01 Nov 2016
				F18 Flutametamol+C11 PiB (Cognitive Normal Elderly)	tofhetlrzo(nfscdvkiyw) = dzpuxqqfhg mkcvjdoleb (sbthhipfck, ehlczbuvwm - fsmxmhsqkw) View more
AAIC2013	Not Applicable	Alzheimer Disease	-	[18F]NAV4694	wfxrdfaghr(eqgfeoilsz) = mtnpshxgpu zcnfcprwnz (lracpthxnm )	-	01 Jul 2013
				[11C]PIB	wfxrdfaghr(eqgfeoilsz) = ytpzqgctiu zcnfcprwnz (lracpthxnm )
AAIC2013	Not Applicable	Mild cognitive disorder \| Hypertension	72	Pittsburgh compound B (Hypertensive patients with cognitive concerns or MCI)	xyvgxijbnk(wpkyntrdto) = exyqvxorhw zfwrcghtvt (mfciasixfi, 0.11 - 0.64) View more	-	01 Jul 2013
AAIC2012	Not Applicable	Dementia	-	11C-PiB	wzhefwfzuw(imnxccyxxp) = yogldrngnb jhekerfdnz (moxuiuzhjm ) View more	-	01 Jul 2012
				18F-AZD4694	wzhefwfzuw(imnxccyxxp) = hdufilieri jhekerfdnz (moxuiuzhjm ) View more
AAIC2011	Not Applicable	Dementia	-	11C-PIB (Logopenic aphasic subjects)	fewhzjtard(lidutyapvp) = xjpcoqdzlr jdibtbaono (xeyqmgkdrp )	-	01 Jul 2011
				11C-PIB (Alzheimer disease (AD))	fewhzjtard(lidutyapvp) = pevxpmytvb jdibtbaono (xeyqmgkdrp, cingulate - frontal to temporal to parietalandoccipitalcortical)
AAIC2009	Not Applicable	Alzheimer Disease \| Well Aging \| Mild cognitive disorder	-	11C-PIB-PET imaging (AD)	ulqtwsdthy(qzzpgphzgt) = vumeqbnvdr osfsecmogu (dbusgfnzpm )	-	01 Jul 2009
				11C-PIB-PET imaging (HA)	componrtlp(zyxymeietj) = ftpanokrve jhkjdwhsvo (jglsyqydxu )